Identification

Name
Atracurium besylate
Accession Number
DB00732  (APRD00806)
Type
Small Molecule
Groups
Approved
Description

A non-depolarizing neuromuscular blocking agent with short duration of action. Its lack of significant cardiovascular effects and its lack of dependence on good kidney function for elimination provide clinical advantage over alternate non-depolarizing neuromuscular blocking agents. [PubChem]

Structure
Thumb
Synonyms
  • 1-[(3,4-Dimethoxyphenyl)methyl]-2-[3-({5-[(3-{1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-2-ium-2-yl}propanoyl)oxy]pentyl}oxy)-3-oxopropyl]-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-2-ium
  • Atracurium besilate
  • Atracurium dibesylate
External IDs
BW 33A / BW-33A / Wellcome 33-A-74
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Atracurium - (for Single Dose )Solution10 mgIntravenousIvax Pharmaceuticals IncorporatedNot applicableNot applicableCanada
Atracurium - (for Multiple Dose Vial - With Preservative)Solution10 mgIntravenousIvax Pharmaceuticals IncorporatedNot applicableNot applicableCanada
Atracurium Besylate InjectionLiquid10 mgIntravenousAbbott1998-02-112007-07-31Canada
Atracurium Besylate InjectionSolution10 mgIntravenousHospira, Inc.1998-07-132012-08-03Canada
Atracurium Besylate InjectionLiquid10 mgIntravenousSandoz Canada Incorporated1998-01-20Not applicableCanada
TracriumLiquid10 mgIntravenousAbbvie1990-12-312012-11-03Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Atracurium BesylateInjection, solution50 mg/5mLIntravenousAuro Medics Pharma Llc2015-04-08Not applicableUs
Atracurium BesylateInjection, solution100 mg/10mLIntravenousAurobindo Pharma2015-04-08Not applicableUs
Atracurium BesylateInjection, solution10 mg/mLIntravenousHospira, Inc.2012-10-18Not applicableUs
Atracurium BesylateInjection, solution100 mg/10mLIntravenousAuro Medics Pharma Llc2015-04-08Not applicableUs
Atracurium BesylateInjection, solution10 mg/mLIntravenousSagent Pharmaceuticals2012-05-01Not applicableUs
Atracurium BesylateInjection, solution10 mg/mLIntravenousHospira, Inc.2012-10-18Not applicableUs
Atracurium BesylateInjection, solution50 mg/5mLIntravenousAurobindo Pharma2015-04-08Not applicableUs
Atracurium BesylateInjection, solution10 mg/mLIntravenousSagent Pharmaceuticals2012-05-01Not applicableUs
Categories
UNII
40AX66P76P
CAS number
64228-81-5
Weight
Average: 1243.49
Monoisotopic: 1242.500406156
Chemical Formula
C65H82N2O18S2
InChI Key
XXZSQOVSEBAPGS-UHFFFAOYSA-L
InChI
InChI=1S/C53H72N2O12.2C6H6O3S/c1-54(22-18-38-32-48(62-7)50(64-9)34-40(38)42(54)28-36-14-16-44(58-3)46(30-36)60-5)24-20-52(56)66-26-12-11-13-27-67-53(57)21-25-55(2)23-19-39-33-49(63-8)51(65-10)35-41(39)43(55)29-37-15-17-45(59-4)47(31-37)61-6;2*7-10(8,9)6-4-2-1-3-5-6/h14-17,30-35,42-43H,11-13,18-29H2,1-10H3;2*1-5H,(H,7,8,9)/q+2;;/p-2
IUPAC Name
1-[(3,4-dimethoxyphenyl)methyl]-2-[3-({5-[(3-{1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-2-ium-2-yl}propanoyl)oxy]pentyl}oxy)-3-oxopropyl]-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-2-ium dibenzenesulfonate
SMILES
[O-]S(=O)(=O)C1=CC=CC=C1.[O-]S(=O)(=O)C1=CC=CC=C1.COC1=CC2=C(C=C1OC)C(CC1=CC(OC)=C(OC)C=C1)[N+](C)(CCC(=O)OCCCCCOC(=O)CC[N+]1(C)CCC3=C(C=C(OC)C(OC)=C3)C1CC1=CC(OC)=C(OC)C=C1)CC2

Pharmacology

Indication

For use, as an adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.

Structured Indications
Not Available
Pharmacodynamics

Atracurium is a nondepolarizing skeletal muscle relaxant. Atracurium can be used most advantageously if muscle twitch response to peripheral nerve stimulation is monitored to assess degree of muscle relaxation. The duration of neuromuscular block produced by Atracurium is approximately one third to one half the duration of block by d-tubocurarine, metocurine, and pancuronium at initially equipotent doses. As with other nondepolarizing neuromuscular blockers, the time to onset of paralysis decreases and the duration of maximum effect increases with increasing doses of Atracurium. Repeated administration of maintenance doses of Atracurium has no cumulative effect on the duration of neuromuscular block if recovery is allowed to begin prior to repeat dosing. Moreover, the time needed to recover from repeat doses does not change with additional doses. Repeat doses can therefore be administered at relatively regular intervals with predictable results.

Mechanism of action

Atracurium antagonizes the neurotransmitter action of acetylcholine by binding competitively with cholinergic receptor sites on the motor end-plate. This antagonism is inhibited, and neuromuscular block reversed, by acetylcholinesterase inhibitors such as neostigmine, edrophonium, and pyridostigmine.

TargetActionsOrganism
ANeuronal acetylcholine receptor subunit alpha-2
inhibitor
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life

The elimination half-life is approximately 20 minutes.

Clearance
Not Available
Toxicity

Excessive doses can be expected to produce enhanced pharmacological effects. Overdosage may increase the risk of histamine release and cardiovascular effects, especially hypotension.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with 1,10-Phenanthroline.Experimental
16-BromoepiandrosteroneAtracurium besylate may increase the adverse neuromuscular activities of 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneAtracurium besylate may increase the adverse neuromuscular activities of 19-norandrostenedione.Experimental, Illicit
5-androstenedioneAtracurium besylate may increase the adverse neuromuscular activities of 5-androstenedione.Experimental, Illicit
AcetyldigitoxinAtracurium besylate may increase the arrhythmogenic activities of Acetyldigitoxin.Approved
AcetyldigoxinAtracurium besylate may increase the arrhythmogenic activities of Acetyldigoxin.Experimental
AclarubicinAclarubicin may increase the respiratory depressant activities of Atracurium besylate.Investigational
AclidiniumAclidinium may increase the anticholinergic activities of Atracurium besylate.Approved
AlclometasoneAtracurium besylate may increase the adverse neuromuscular activities of Alclometasone.Approved
AlcuroniumThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Alcuronium.Experimental
AldosteroneAtracurium besylate may increase the adverse neuromuscular activities of Aldosterone.Experimental
AlfentanilThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Alfentanil.Approved, Illicit
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Alphaprodine.Illicit
AmbenoniumThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Ambenonium.Approved
AmcinonideAtracurium besylate may increase the adverse neuromuscular activities of Amcinonide.Approved
AmikacinAmikacin may increase the respiratory depressant activities of Atracurium besylate.Approved, Vet Approved
AmlodipineAmlodipine may increase the neuromuscular blocking activities of Atracurium besylate.Approved
AmrinoneAmrinone may increase the neuromuscular blocking activities of Atracurium besylate.Approved
AmrubicinAmrubicin may increase the respiratory depressant activities of Atracurium besylate.Approved, Investigational
AndrostenedioneAtracurium besylate may increase the adverse neuromuscular activities of Androstenedione.Experimental, Illicit
AnecortaveAtracurium besylate may increase the adverse neuromuscular activities of Anecortave.Investigational
anecortave acetateAtracurium besylate may increase the adverse neuromuscular activities of anecortave acetate.Investigational
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Atracurium besylate.Approved
annamycinannamycin may increase the respiratory depressant activities of Atracurium besylate.Investigational
ApramycinApramycin may increase the respiratory depressant activities of Atracurium besylate.Experimental, Vet Approved
ArbekacinArbekacin may increase the respiratory depressant activities of Atracurium besylate.Approved
AtamestaneAtracurium besylate may increase the adverse neuromuscular activities of Atamestane.Investigational
AtracuriumThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Atracurium.Experimental
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Atracurium besylate.Approved, Vet Approved
AzelnidipineAzelnidipine may increase the neuromuscular blocking activities of Atracurium besylate.Approved
AzimilideAzimilide may increase the neuromuscular blocking activities of Atracurium besylate.Investigational
BarnidipineBarnidipine may increase the neuromuscular blocking activities of Atracurium besylate.Approved
Beclomethasone dipropionateAtracurium besylate may increase the adverse neuromuscular activities of Beclomethasone dipropionate.Approved, Investigational
BekanamycinBekanamycin may increase the respiratory depressant activities of Atracurium besylate.Experimental
BenactyzineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Benactyzine.Withdrawn
BencyclaneBencyclane may increase the neuromuscular blocking activities of Atracurium besylate.Experimental
BendroflumethiazideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Atracurium besylate.Approved
BenidipineBenidipine may increase the neuromuscular blocking activities of Atracurium besylate.Approved
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Atracurium besylate.Approved
BepridilBepridil may increase the neuromuscular blocking activities of Atracurium besylate.Approved, Withdrawn
BetamethasoneAtracurium besylate may increase the adverse neuromuscular activities of Betamethasone.Approved, Vet Approved
BezitramideThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Bezitramide.Experimental, Illicit, Withdrawn
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Atracurium besylate.Approved
BornaprineThe risk or severity of adverse effects can be increased when Bornaprine is combined with Atracurium besylate.Experimental
Botulinum Toxin Type ABotulinum Toxin Type A may increase the neuromuscular blocking activities of Atracurium besylate.Approved, Investigational
Botulinum Toxin Type BAtracurium besylate may increase the neuromuscular blocking activities of Botulinum Toxin Type B.Approved
BudesonideAtracurium besylate may increase the adverse neuromuscular activities of Budesonide.Approved
BumetanideBumetanide may decrease the neuromuscular blocking activities of Atracurium besylate.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Butorphanol.Approved, Illicit, Vet Approved
CapreomycinCapreomycin may increase the neuromuscular blocking activities of Atracurium besylate.Approved
CarboxyamidotriazoleCarboxyamidotriazole may increase the neuromuscular blocking activities of Atracurium besylate.Investigational
CarfentanilThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Carfentanil.Illicit, Vet Approved
CaroverineCaroverine may increase the neuromuscular blocking activities of Atracurium besylate.Experimental
ChlorothiazideThe serum concentration of Chlorothiazide can be increased when it is combined with Atracurium besylate.Approved, Vet Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Chlorphenoxamine.Withdrawn
ChlortetracyclineChlortetracycline may increase the neuromuscular blocking activities of Atracurium besylate.Approved, Vet Approved
ChlorthalidoneThe serum concentration of Chlorthalidone can be increased when it is combined with Atracurium besylate.Approved
CiclesonideAtracurium besylate may increase the adverse neuromuscular activities of Ciclesonide.Approved, Investigational
CilnidipineCilnidipine may increase the neuromuscular blocking activities of Atracurium besylate.Approved
CimetropiumAtracurium besylate may increase the anticholinergic activities of Cimetropium.Experimental
CinnarizineCinnarizine may increase the neuromuscular blocking activities of Atracurium besylate.Approved
ClevidipineClevidipine may increase the neuromuscular blocking activities of Atracurium besylate.Approved
ClindamycinClindamycin may increase the neuromuscular blocking activities of Atracurium besylate.Approved, Vet Approved
ClobetasolAtracurium besylate may increase the adverse neuromuscular activities of Clobetasol.Investigational
Clobetasol propionateAtracurium besylate may increase the adverse neuromuscular activities of Clobetasol propionate.Approved
ClobetasoneAtracurium besylate may increase the adverse neuromuscular activities of Clobetasone.Approved
ClocortoloneAtracurium besylate may increase the adverse neuromuscular activities of Clocortolone.Approved
CodeineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Codeine.Approved, Illicit
ColistimethateColistimethate may increase the neuromuscular blocking activities of Atracurium besylate.Approved, Vet Approved
Cortexolone 17α-propionateAtracurium besylate may increase the adverse neuromuscular activities of Cortexolone 17α-propionate.Investigational
CorticosteroneAtracurium besylate may increase the adverse neuromuscular activities of Corticosterone.Experimental
Cortisone acetateAtracurium besylate may increase the adverse neuromuscular activities of Cortisone acetate.Approved
CoumaphosThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Coumaphos.Vet Approved
CyclopenthiazideThe serum concentration of Cyclopenthiazide can be increased when it is combined with Atracurium besylate.Experimental
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Atracurium besylate.Approved
CyclosporineCyclosporine may increase the neuromuscular blocking activities of Atracurium besylate.Approved, Investigational, Vet Approved
CymarinAtracurium besylate may increase the arrhythmogenic activities of Cymarin.Experimental
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Atracurium besylate.Approved, Investigational
DarodipineDarodipine may increase the neuromuscular blocking activities of Atracurium besylate.Experimental
DaunorubicinDaunorubicin may increase the respiratory depressant activities of Atracurium besylate.Approved
DecamethoniumThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Decamethonium.Approved
DemecariumThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Demecarium.Approved
DemeclocyclineDemeclocycline may increase the neuromuscular blocking activities of Atracurium besylate.Approved
DesfluraneDesflurane may increase the neuromuscular blocking activities of Atracurium besylate.Approved
DeslanosideAtracurium besylate may increase the arrhythmogenic activities of Deslanoside.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Desloratadine.Approved, Investigational
DesoximetasoneAtracurium besylate may increase the adverse neuromuscular activities of Desoximetasone.Approved
Desoxycorticosterone acetateAtracurium besylate may increase the adverse neuromuscular activities of Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateAtracurium besylate may increase the adverse neuromuscular activities of Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneAtracurium besylate may increase the adverse neuromuscular activities of Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateAtracurium besylate may increase the adverse neuromuscular activities of Dexamethasone isonicotinate.Vet Approved
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Atracurium besylate.Withdrawn
DextromoramideThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Dezocine.Approved
DibekacinDibekacin may increase the respiratory depressant activities of Atracurium besylate.Experimental
DichlorvosThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Dichlorvos.Vet Approved
DicyclomineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Dicyclomine.Approved
Diethyl etherDiethyl ether may increase the neuromuscular blocking activities of Atracurium besylate.Experimental
DiflorasoneAtracurium besylate may increase the adverse neuromuscular activities of Diflorasone.Approved
DifluocortoloneAtracurium besylate may increase the adverse neuromuscular activities of Difluocortolone.Approved
DifluprednateAtracurium besylate may increase the adverse neuromuscular activities of Difluprednate.Approved
DigitoxinAtracurium besylate may increase the arrhythmogenic activities of Digitoxin.Approved
DigoxinAtracurium besylate may increase the arrhythmogenic activities of Digoxin.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Dihydrocodeine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Dihydromorphine.Experimental, Illicit
DihydrostreptomycinDihydrostreptomycin may increase the respiratory depressant activities of Atracurium besylate.Vet Approved
DiltiazemDiltiazem may increase the neuromuscular blocking activities of Atracurium besylate.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Diphenoxylate.Approved, Illicit
DistigmineThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Distigmine.Experimental
DonepezilThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Donepezil.Approved
DotarizineDotarizine may increase the neuromuscular blocking activities of Atracurium besylate.Investigational
DoxorubicinDoxorubicin may increase the respiratory depressant activities of Atracurium besylate.Approved, Investigational
DoxycyclineDoxycycline may increase the neuromuscular blocking activities of Atracurium besylate.Approved, Investigational, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with DPDPE.Investigational
DronabinolAtracurium besylate may increase the tachycardic activities of Dronabinol.Approved, Illicit
EchothiophateThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Echothiophate.Approved
EdrophoniumThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Edrophonium.Approved
EfonidipineEfonidipine may increase the neuromuscular blocking activities of Atracurium besylate.Approved
EluxadolineAtracurium besylate may increase the constipating activities of Eluxadoline.Approved
EmeproniumThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Emepronium.Experimental
EnfluraneEnflurane may increase the neuromuscular blocking activities of Atracurium besylate.Approved, Vet Approved
EperisoneEperisone may increase the neuromuscular blocking activities of Atracurium besylate.Approved, Investigational
EpirubicinEpirubicin may increase the respiratory depressant activities of Atracurium besylate.Approved
EquileninAtracurium besylate may increase the adverse neuromuscular activities of Equilenin.Experimental
EquilinAtracurium besylate may increase the adverse neuromuscular activities of Equilin.Approved
EstroneAtracurium besylate may increase the adverse neuromuscular activities of Estrone.Approved
Estrone sulfateAtracurium besylate may increase the adverse neuromuscular activities of Estrone sulfate.Approved
Etacrynic acidEtacrynic acid may decrease the neuromuscular blocking activities of Atracurium besylate.Approved
EtanautineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Etanautine.Experimental
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Atracurium besylate.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Ethylmorphine.Approved, Illicit
EtorphineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Etorphine.Illicit, Vet Approved
EtybenzatropineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Etybenzatropine.Experimental
FelodipineFelodipine may increase the neuromuscular blocking activities of Atracurium besylate.Approved, Investigational
FendilineFendiline may increase the neuromuscular blocking activities of Atracurium besylate.Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FenthionThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Fenthion.Vet Approved
FesoterodineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Fesoterodine.Approved
fluasteroneAtracurium besylate may increase the adverse neuromuscular activities of fluasterone.Investigational
FludrocortisoneAtracurium besylate may increase the adverse neuromuscular activities of Fludrocortisone.Approved
FlumethasoneAtracurium besylate may increase the adverse neuromuscular activities of Flumethasone.Approved, Vet Approved
FlunarizineFlunarizine may increase the neuromuscular blocking activities of Atracurium besylate.Approved
Fluocinolone AcetonideAtracurium besylate may increase the adverse neuromuscular activities of Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideAtracurium besylate may increase the adverse neuromuscular activities of Fluocinonide.Approved, Investigational
FluocortoloneAtracurium besylate may increase the adverse neuromuscular activities of Fluocortolone.Approved, Withdrawn
FluorometholoneAtracurium besylate may increase the adverse neuromuscular activities of Fluorometholone.Approved
FluprednideneAtracurium besylate may increase the adverse neuromuscular activities of Fluprednidene.Approved, Withdrawn
FluprednisoloneAtracurium besylate may increase the adverse neuromuscular activities of Fluprednisolone.Approved
FlurandrenolideAtracurium besylate may increase the adverse neuromuscular activities of Flurandrenolide.Approved
FormestaneAtracurium besylate may increase the adverse neuromuscular activities of Formestane.Approved, Investigational, Withdrawn
FosphenytoinFosphenytoin may decrease the neuromuscular blocking activities of Atracurium besylate.Approved
FramycetinFramycetin may increase the respiratory depressant activities of Atracurium besylate.Approved
FurosemideFurosemide may decrease the neuromuscular blocking activities of Atracurium besylate.Approved, Vet Approved
GabapentinGabapentin may increase the neuromuscular blocking activities of Atracurium besylate.Approved, Investigational
GalantamineThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Galantamine.Approved
GallamineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Gallamine.Experimental
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Atracurium besylate.Approved
GallopamilGallopamil may increase the neuromuscular blocking activities of Atracurium besylate.Investigational
GeneticinGeneticin may increase the respiratory depressant activities of Atracurium besylate.Experimental
GentamicinGentamicin may increase the respiratory depressant activities of Atracurium besylate.Approved, Vet Approved
GENTAMICIN C1AGENTAMICIN C1A may increase the respiratory depressant activities of Atracurium besylate.Experimental
Ginkgo bilobaThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Ginkgo biloba.Approved, Nutraceutical
GitoformateAtracurium besylate may increase the arrhythmogenic activities of Gitoformate.Experimental
Glucagon recombinantThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Glucagon recombinant.Approved
GlycopyrroniumAtracurium besylate may increase the anticholinergic activities of Glycopyrronium.Approved, Investigational, Vet Approved
GPX-150GPX-150 may increase the respiratory depressant activities of Atracurium besylate.Investigational
HalothaneHalothane may increase the neuromuscular blocking activities of Atracurium besylate.Approved, Vet Approved
HE3286Atracurium besylate may increase the adverse neuromuscular activities of HE3286.Investigational
HeroinThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Heroin.Approved, Illicit
HexamethoniumThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Hexamethonium.Experimental
HomatropineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Homatropine.Approved
Huperzine AThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Huperzine A.Investigational
HydrochlorothiazideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Atracurium besylate.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Hydrocodone.Approved, Illicit
HydrocortisoneAtracurium besylate may increase the adverse neuromuscular activities of Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe serum concentration of Hydroflumethiazide can be increased when it is combined with Atracurium besylate.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Hydromorphone.Approved, Illicit
Hygromycin BHygromycin B may increase the respiratory depressant activities of Atracurium besylate.Vet Approved
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Atracurium besylate.Approved
IdarubicinIdarubicin may increase the respiratory depressant activities of Atracurium besylate.Approved
IndapamideThe serum concentration of Indapamide can be increased when it is combined with Atracurium besylate.Approved
INNO-206INNO-206 may increase the respiratory depressant activities of Atracurium besylate.Investigational
IpidacrineThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Ipidacrine.Experimental
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Atracurium besylate.Approved
IsepamicinIsepamicin may increase the respiratory depressant activities of Atracurium besylate.Experimental
IsofluraneIsoflurane may increase the neuromuscular blocking activities of Atracurium besylate.Approved, Vet Approved
IsoflurophateThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Isoflurophate.Approved, Withdrawn
IsradipineIsradipine may increase the neuromuscular blocking activities of Atracurium besylate.Approved
IstaroximeAtracurium besylate may increase the adverse neuromuscular activities of Istaroxime.Investigational
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Atracurium besylate.Investigational
KanamycinKanamycin may increase the respiratory depressant activities of Atracurium besylate.Approved, Vet Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Ketobemidone.Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Atracurium besylate.Approved
LacidipineLacidipine may increase the neuromuscular blocking activities of Atracurium besylate.Approved
LamotrigineLamotrigine may increase the neuromuscular blocking activities of Atracurium besylate.Approved, Investigational
Lanatoside CAtracurium besylate may increase the arrhythmogenic activities of Lanatoside C.Experimental
LercanidipineLercanidipine may increase the neuromuscular blocking activities of Atracurium besylate.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Levomethadyl Acetate.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Levorphanol.Approved
LidoflazineLidoflazine may increase the neuromuscular blocking activities of Atracurium besylate.Experimental
LincomycinLincomycin may increase the neuromuscular blocking activities of Atracurium besylate.Approved, Vet Approved
LithiumLithium may increase the neuromuscular blocking activities of Atracurium besylate.Approved
LofentanilThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Lofentanil.Illicit
Magnesium HydroxideMagnesium Hydroxide may increase the neuromuscular blocking activities of Atracurium besylate.Approved
Magnesium oxideMagnesium oxide may increase the neuromuscular blocking activities of Atracurium besylate.Approved
Magnesium salicylateMagnesium salicylate may increase the neuromuscular blocking activities of Atracurium besylate.Approved
Magnesium SulfateMagnesium Sulfate may increase the neuromuscular blocking activities of Atracurium besylate.Approved, Vet Approved
MalathionThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Malathion.Approved, Investigational
ManidipineManidipine may increase the neuromuscular blocking activities of Atracurium besylate.Approved
MazaticolThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Mazaticol.Experimental
ME-609Atracurium besylate may increase the adverse neuromuscular activities of ME-609.Investigational
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Atracurium besylate.Approved
MedrysoneAtracurium besylate may increase the adverse neuromuscular activities of Medrysone.Approved
MefloquineThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Mefloquine.Approved
MelengestrolAtracurium besylate may increase the adverse neuromuscular activities of Melengestrol.Vet Approved
MemantineThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Memantine.Approved, Investigational
MeptazinolThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Meptazinol.Experimental
MethadoneThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Methadyl Acetate.Approved, Illicit
Methanesulfonyl FluorideThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Methanesulfonyl Fluoride.Investigational
MethanthelineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Methantheline.Approved
MethoxyfluraneMethoxyflurane may increase the neuromuscular blocking activities of Atracurium besylate.Approved, Vet Approved
MethyclothiazideThe serum concentration of Methyclothiazide can be increased when it is combined with Atracurium besylate.Approved
Methyl salicylateThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Methyl salicylate.Approved, Vet Approved
MethylprednisoloneAtracurium besylate may increase the adverse neuromuscular activities of Methylprednisolone.Approved, Vet Approved
MetildigoxinAtracurium besylate may increase the arrhythmogenic activities of Metildigoxin.Experimental
MetixeneThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Metixene.Approved
MetoclopramideThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Metoclopramide.Approved, Investigational
MetolazoneThe serum concentration of Metolazone can be increased when it is combined with Atracurium besylate.Approved
MetrizamideMetrizamide may increase the respiratory depressant activities of Atracurium besylate.Approved
MianserinMianserin may increase the anticholinergic activities of Atracurium besylate.Approved
MibefradilMibefradil may increase the neuromuscular blocking activities of Atracurium besylate.Withdrawn
MicronomicinMicronomicin may increase the respiratory depressant activities of Atracurium besylate.Experimental
MinaprineThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Minaprine.Approved
MinocyclineMinocycline may increase the neuromuscular blocking activities of Atracurium besylate.Approved, Investigational
MirabegronThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Mirabegron.Approved
MorphineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Morphine.Approved, Investigational
NabiloneAtracurium besylate may increase the tachycardic activities of Nabilone.Approved, Investigational
NaftopidilNaftopidil may increase the neuromuscular blocking activities of Atracurium besylate.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Nalbuphine.Approved
NCX 1022Atracurium besylate may increase the adverse neuromuscular activities of NCX 1022.Investigational
NeamineNeamine may increase the respiratory depressant activities of Atracurium besylate.Experimental
NeomycinNeomycin may increase the respiratory depressant activities of Atracurium besylate.Approved, Vet Approved
NeostigmineThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Neostigmine.Approved, Vet Approved
NetilmicinNetilmicin may increase the respiratory depressant activities of Atracurium besylate.Approved
NicardipineNicardipine may increase the neuromuscular blocking activities of Atracurium besylate.Approved
NicomorphineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Nicomorphine.Experimental
NifedipineNifedipine may increase the neuromuscular blocking activities of Atracurium besylate.Approved
NiguldipineNiguldipine may increase the neuromuscular blocking activities of Atracurium besylate.Experimental
NiludipineNiludipine may increase the neuromuscular blocking activities of Atracurium besylate.Experimental
NilvadipineNilvadipine may increase the neuromuscular blocking activities of Atracurium besylate.Approved
NimesulideNimesulide may increase the neuromuscular blocking activities of Atracurium besylate.Approved, Withdrawn
NimodipineNimodipine may increase the neuromuscular blocking activities of Atracurium besylate.Approved
NisoldipineNisoldipine may increase the neuromuscular blocking activities of Atracurium besylate.Approved
NitrendipineNitrendipine may increase the neuromuscular blocking activities of Atracurium besylate.Approved
Nitrous oxideNitrous oxide may increase the neuromuscular blocking activities of Atracurium besylate.Approved, Vet Approved
NormethadoneThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Normethadone.Approved, Illicit
OleandrinAtracurium besylate may increase the arrhythmogenic activities of Oleandrin.Experimental
Oleoyl-estroneAtracurium besylate may increase the adverse neuromuscular activities of Oleoyl-estrone.Investigational
OpiumThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Opium.Approved, Illicit
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Atracurium besylate.Approved
OtiloniumThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Otilonium.Experimental
OuabainAtracurium besylate may increase the arrhythmogenic activities of Ouabain.Approved
OxitropiumThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Oxitropium.Investigational
OxybutyninThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Oxybutynin.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Oxymorphone.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Atracurium besylate.Approved
PancuroniumThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Pancuronium.Approved
ParamethasoneAtracurium besylate may increase the adverse neuromuscular activities of Paramethasone.Approved
ParaoxonThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Paraoxon.Experimental
ParomomycinParomomycin may increase the respiratory depressant activities of Atracurium besylate.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Pentazocine.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Pentolinium.Approved
PerhexilinePerhexiline may increase the neuromuscular blocking activities of Atracurium besylate.Approved
PeruvosideAtracurium besylate may increase the arrhythmogenic activities of Peruvoside.Experimental
PethidineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Pethidine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Phenazocine.Experimental
PhenglutarimideThe risk or severity of adverse effects can be increased when Phenglutarimide is combined with Atracurium besylate.Experimental
PhenoperidineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Phenoperidine.Experimental
PhenytoinPhenytoin may decrease the neuromuscular blocking activities of Atracurium besylate.Approved, Vet Approved
PhysostigmineThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Physostigmine.Approved
PinaveriumPinaverium may increase the neuromuscular blocking activities of Atracurium besylate.Approved
PipecuroniumThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Pipecuronium.Approved
PirarubicinPirarubicin may increase the respiratory depressant activities of Atracurium besylate.Investigational
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Atracurium besylate.Approved
PiretanidePiretanide may decrease the neuromuscular blocking activities of Atracurium besylate.Experimental
PiritramideThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Piritramide.Investigational
PirlimycinPirlimycin may increase the neuromuscular blocking activities of Atracurium besylate.Vet Approved
PlazomicinPlazomicin may increase the respiratory depressant activities of Atracurium besylate.Investigational
PlicamycinPlicamycin may increase the respiratory depressant activities of Atracurium besylate.Approved, Withdrawn
Polymyxin B SulfatePolymyxin B Sulfate may increase the neuromuscular blocking activities of Atracurium besylate.Approved, Vet Approved
PolythiazideThe serum concentration of Polythiazide can be increased when it is combined with Atracurium besylate.Approved
Potassium ChlorideAtracurium besylate may increase the ulcerogenic activities of Potassium Chloride.Approved, Withdrawn
PramlintidePramlintide may increase the anticholinergic activities of Atracurium besylate.Approved, Investigational
PrasteroneAtracurium besylate may increase the adverse neuromuscular activities of Prasterone.Approved, Nutraceutical
Prasterone sulfateAtracurium besylate may increase the adverse neuromuscular activities of Prasterone sulfate.Investigational
PrednicarbateAtracurium besylate may increase the adverse neuromuscular activities of Prednicarbate.Approved
PrednisoloneAtracurium besylate may increase the adverse neuromuscular activities of Prednisolone.Approved, Vet Approved
PrednisoneAtracurium besylate may increase the adverse neuromuscular activities of Prednisone.Approved, Vet Approved
PregabalinPregabalin may increase the neuromuscular blocking activities of Atracurium besylate.Approved, Illicit, Investigational
PregnenoloneAtracurium besylate may increase the adverse neuromuscular activities of Pregnenolone.Experimental
PrenylaminePrenylamine may increase the neuromuscular blocking activities of Atracurium besylate.Withdrawn
ProcainamideProcainamide may increase the neuromuscular blocking activities of Atracurium besylate.Approved
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Atracurium besylate.Approved
PropanthelineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Propantheline.Approved
PropiverineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Propiverine.Investigational
ProscillaridinAtracurium besylate may increase the arrhythmogenic activities of Proscillaridin.Experimental
PuromycinPuromycin may increase the respiratory depressant activities of Atracurium besylate.Experimental
PyridostigmineThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Pyridostigmine.Approved
QuinethazoneThe serum concentration of Quinethazone can be increased when it is combined with Atracurium besylate.Approved
QuinidineQuinidine may increase the neuromuscular blocking activities of Atracurium besylate.Approved
QuinineQuinine may increase the neuromuscular blocking activities of Atracurium besylate.Approved
RamosetronAtracurium besylate may increase the constipating activities of Ramosetron.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Remifentanil.Approved
RibostamycinRibostamycin may increase the respiratory depressant activities of Atracurium besylate.Approved
RimexoloneAtracurium besylate may increase the adverse neuromuscular activities of Rimexolone.Approved
RisedronateRisedronate may increase the neuromuscular blocking activities of Atracurium besylate.Approved, Investigational
RivastigmineThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Rivastigmine.Approved, Investigational
SabarubicinSabarubicin may increase the respiratory depressant activities of Atracurium besylate.Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Atracurium besylate.Approved
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Scopolamine butylbromide.Approved, Vet Approved
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Atracurium besylate.Approved, Investigational
SevofluraneSevoflurane may increase the neuromuscular blocking activities of Atracurium besylate.Approved, Vet Approved
SisomicinSisomicin may increase the respiratory depressant activities of Atracurium besylate.Investigational
SolifenacinThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Solifenacin.Approved
SP1049CSP1049C may increase the respiratory depressant activities of Atracurium besylate.Investigational
SpectinomycinSpectinomycin may increase the respiratory depressant activities of Atracurium besylate.Approved, Vet Approved
SpironolactoneSpironolactone may increase the neuromuscular blocking activities of Atracurium besylate.Approved
StreptomycinStreptomycin may increase the respiratory depressant activities of Atracurium besylate.Approved, Vet Approved
StreptozocinStreptozocin may increase the respiratory depressant activities of Atracurium besylate.Approved
SufentanilThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Sufentanil.Approved, Investigational
SulpirideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Atracurium besylate.Approved
TacrineThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Tacrine.Withdrawn
TapentadolThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Tapentadol.Approved
TerodilineTerodiline may increase the neuromuscular blocking activities of Atracurium besylate.Experimental
TetrahydropalmatineTetrahydropalmatine may increase the neuromuscular blocking activities of Atracurium besylate.Investigational
TilidineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Tilidine.Experimental
TiotropiumAtracurium besylate may increase the anticholinergic activities of Tiotropium.Approved
TixocortolAtracurium besylate may increase the adverse neuromuscular activities of Tixocortol.Approved
TobramycinTobramycin may increase the respiratory depressant activities of Atracurium besylate.Approved, Investigational
Tolfenamic AcidTolfenamic Acid may increase the neuromuscular blocking activities of Atracurium besylate.Approved
TolterodineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Tolterodine.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Topiramate.Approved
TorasemideTorasemide may decrease the neuromuscular blocking activities of Atracurium besylate.Approved
TramadolThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Tramadol.Approved, Investigational
TranilastTranilast may increase the neuromuscular blocking activities of Atracurium besylate.Approved, Investigational
TriamcinoloneAtracurium besylate may increase the adverse neuromuscular activities of Triamcinolone.Approved, Vet Approved
TrichlorfonThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Trichlorfon.Vet Approved
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Atracurium besylate.Approved, Vet Approved
TrichloroethyleneTrichloroethylene may increase the neuromuscular blocking activities of Atracurium besylate.Experimental
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Atracurium besylate.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Trimethaphan.Approved
TropatepineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Tropatepine.Experimental
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Atracurium besylate.Approved
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Atracurium besylate.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Tubocurarine.Approved
UmeclidiniumUmeclidinium may increase the anticholinergic activities of Atracurium besylate.Approved
ValrubicinValrubicin may increase the respiratory depressant activities of Atracurium besylate.Approved
VancomycinVancomycin may increase the neuromuscular blocking activities of Atracurium besylate.Approved
VecuroniumThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Vecuronium.Approved
VerapamilVerapamil may increase the neuromuscular blocking activities of Atracurium besylate.Approved
VinpocetineVinpocetine may increase the neuromuscular blocking activities of Atracurium besylate.Investigational
XenonXenon may increase the neuromuscular blocking activities of Atracurium besylate.Experimental
XylometazolineXylometazoline may increase the neuromuscular blocking activities of Atracurium besylate.Approved
ZiconotideZiconotide may increase the neuromuscular blocking activities of Atracurium besylate.Approved
Zoptarelin doxorubicinZoptarelin doxorubicin may increase the respiratory depressant activities of Atracurium besylate.Investigational
ZorubicinZorubicin may increase the respiratory depressant activities of Atracurium besylate.Experimental
Food Interactions
Not Available

References

Synthesis Reference

Steven A. Chamberlin, Ashok V. Bhatia, Deborah A. Davis, Keith A. Drengler, "Process for the preparation and isolation of atracurium besylate." U.S. Patent US5684154, issued September, 1995.

US5684154
General References
Not Available
External Links
KEGG Drug
D00758
PubChem Compound
47320
PubChem Substance
46504689
ChemSpider
43068
BindingDB
50149881
ChEBI
2915
ChEMBL
CHEMBL1200527
Therapeutic Targets Database
DAP000105
PharmGKB
PA164776840
RxList
RxList Drug Page
Wikipedia
Atracurium
AHFS Codes
  • 12:20.20 — Neuromuscular Blocking Agents
MSDS
Download (162 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedSupportive CareQuality of Ocular Akinesia (Onset and Duration)1
Not AvailableNot Yet RecruitingSupportive CareFemale Breast Cancer1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
Injection, solutionIntravenous10 mg/mL
Injection, solutionIntravenous100 mg/10mL
Injection, solutionIntravenous50 mg/5mL
SolutionIntravenous10 mg
LiquidIntravenous10 mg
Prices
Unit descriptionCostUnit
Atracurium 10 mg/ml vial0.96USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)85-90Stenlake, J.B., Waigh, R.D., Dewar,G.H., Urwin, J. and Dhar, N.C.; U.S. Patent 4,179,507 December 18,1979; assigned to BurroughsWellcome Company.
water solubilityMiscibleNot Available
Predicted Properties
PropertyValueSource
Water Solubility4.17e-05 mg/mLALOGPS
logP3.34ALOGPS
logP-0.96ChemAxon
logS-7.5ALOGPS
pKa (Strongest Acidic)19.02ChemAxon
pKa (Strongest Basic)-4.1ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count10ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area126.44 Å2ChemAxon
Rotatable Bond Count28ChemAxon
Refractivity280.68 m3·mol-1ChemAxon
Polarizability104.67 Å3ChemAxon
Number of Rings8ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.9907
Blood Brain Barrier+0.9367
Caco-2 permeable+0.6226
P-glycoprotein substrateSubstrate0.8276
P-glycoprotein inhibitor IInhibitor0.5282
P-glycoprotein inhibitor IIInhibitor0.6888
Renal organic cation transporterNon-inhibitor0.5447
CYP450 2C9 substrateNon-substrate0.8354
CYP450 2D6 substrateNon-substrate0.6895
CYP450 3A4 substrateSubstrate0.6913
CYP450 1A2 substrateNon-inhibitor0.9225
CYP450 2C9 inhibitorNon-inhibitor0.9468
CYP450 2D6 inhibitorNon-inhibitor0.8816
CYP450 2C19 inhibitorNon-inhibitor0.9107
CYP450 3A4 inhibitorNon-inhibitor0.8359
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9068
Ames testNon AMES toxic0.7032
CarcinogenicityNon-carcinogens0.9241
BiodegradationNot ready biodegradable0.7843
Rat acute toxicity2.5245 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8459
hERG inhibition (predictor II)Non-inhibitor0.5169
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzylisoquinolines. These are organic compounds containing an isoquinoline to which a benzyl group is attached.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Isoquinolines and derivatives
Sub Class
Benzylisoquinolines
Direct Parent
Benzylisoquinolines
Alternative Parents
Benzenesulfonic acids and derivatives / Dimethoxybenzenes / Tetrahydroisoquinolines / 1-sulfo,2-unsubstituted aromatic compounds / Benzenesulfonyl compounds / Phenoxy compounds / Anisoles / Aralkylamines / Alkyl aryl ethers / Dicarboxylic acids and derivatives
show 11 more
Substituents
Benzylisoquinoline / Tetrahydroisoquinoline / Benzenesulfonate / O-dimethoxybenzene / Dimethoxybenzene / Arylsulfonic acid or derivatives / Benzenesulfonyl group / 1-sulfo,2-unsubstituted aromatic compound / Phenoxy compound / Anisole
show 30 more
Molecular Framework
Not Available
External Descriptors
quaternary ammonium salt, organosulfonate salt (CHEBI:2915)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Drug binding
Specific Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Gene Name
CHRNA2
Uniprot ID
Q15822
Uniprot Name
Neuronal acetylcholine receptor subunit alpha-2
Molecular Weight
59764.82 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Jonsson Fagerlund M, Dabrowski M, Eriksson LI: Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor. Anesthesiology. 2009 Jun;110(6):1244-52. doi: 10.1097/ALN.0b013e31819fade3. [PubMed:19417616]

Drug created on June 13, 2005 07:24 / Updated on October 21, 2017 19:25